Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders

Kristen E. Voss, Roni Jacob Bollag, Nicole Fussell, Charya By, Daniel J Sheehan, Wendy B Bollag

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Non-melanoma skin cancers (NMSCs) and psoriasis represent common hyperproliferative skin disorders, with approximately one million new NMSC diagnoses each year in the United States alone and a psoriasis prevalence of about 2% worldwide. We recently demonstrated that the glycerol channel, aquaporin-3 (AQP3) and the enzyme phospholipase D2 (PLD2) interact functionally in epidermal keratinocytes of the skin to inhibit their proliferation. However, others have suggested that AQP3 is pro-proliferative in keratinocytes and is upregulated in the NMSC, squamous cell carcinoma (SCC). To evaluate the AQP3/PLD2 signaling module in skin diseases, we determined their levels in SCC, basal cell carcinoma (BCC) and psoriasis as compared to normal epidermis. Skin biopsies with the appropriate diagnoses (10 normal, 5 SCC, 13 BCC and 10 plaque psoriasis samples) were obtained from the pathology archives and examined by immunohistochemistry using antibodies recognizing AQP3 and PLD2. In normal epidermis AQP3, an integral membrane protein, was localized mainly to the plasma membrane and PLD2 to the cell periphery, particularly in suprabasal layers. In BCC, AQP3 and PLD2 levels were reduced as compared to the normal-appearing overlying epidermis. In SCC, AQP3 staining was "patchy," with areas of reduced AQP3 immunoreactivity exhibiting positivity for Ki67, a marker of proliferation. PLD2 staining was unchanged in SCC. In psoriasis, AQP3 staining was usually observed in the cytoplasm rather than in the membrane. Also, in the majority of psoriatic samples, PLD2 showed weak immunoreactivity or aberrant localization. These results suggest that abnormalities in the AQP3/PLD2 signaling module correlate with hyperproliferation in psoriasis and the NMSCs.

Original languageEnglish (US)
Pages (from-to)591-600
Number of pages10
JournalArchives of Dermatological Research
Volume303
Issue number8
DOIs
StatePublished - Oct 1 2011

Fingerprint

Aquaporin 3
Skin
Psoriasis
Skin Neoplasms
Squamous Cell Carcinoma
Basal Cell Carcinoma
Epidermis
Staining and Labeling
Keratinocytes
phospholipase D2
Skin Diseases
Glycerol
Membrane Proteins
Cytoplasm

Keywords

  • Aquaporin-3
  • Basal cell carcinoma
  • Epidermis
  • Keratinocytes
  • Phospholipase D2
  • Skin
  • Skin cancer
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Dermatology

Cite this

Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders. / Voss, Kristen E.; Bollag, Roni Jacob; Fussell, Nicole; By, Charya; Sheehan, Daniel J; Bollag, Wendy B.

In: Archives of Dermatological Research, Vol. 303, No. 8, 01.10.2011, p. 591-600.

Research output: Contribution to journalArticle

@article{a8d90d027c2d40e19be02d7cb15799e6,
title = "Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders",
abstract = "Non-melanoma skin cancers (NMSCs) and psoriasis represent common hyperproliferative skin disorders, with approximately one million new NMSC diagnoses each year in the United States alone and a psoriasis prevalence of about 2{\%} worldwide. We recently demonstrated that the glycerol channel, aquaporin-3 (AQP3) and the enzyme phospholipase D2 (PLD2) interact functionally in epidermal keratinocytes of the skin to inhibit their proliferation. However, others have suggested that AQP3 is pro-proliferative in keratinocytes and is upregulated in the NMSC, squamous cell carcinoma (SCC). To evaluate the AQP3/PLD2 signaling module in skin diseases, we determined their levels in SCC, basal cell carcinoma (BCC) and psoriasis as compared to normal epidermis. Skin biopsies with the appropriate diagnoses (10 normal, 5 SCC, 13 BCC and 10 plaque psoriasis samples) were obtained from the pathology archives and examined by immunohistochemistry using antibodies recognizing AQP3 and PLD2. In normal epidermis AQP3, an integral membrane protein, was localized mainly to the plasma membrane and PLD2 to the cell periphery, particularly in suprabasal layers. In BCC, AQP3 and PLD2 levels were reduced as compared to the normal-appearing overlying epidermis. In SCC, AQP3 staining was {"}patchy,{"} with areas of reduced AQP3 immunoreactivity exhibiting positivity for Ki67, a marker of proliferation. PLD2 staining was unchanged in SCC. In psoriasis, AQP3 staining was usually observed in the cytoplasm rather than in the membrane. Also, in the majority of psoriatic samples, PLD2 showed weak immunoreactivity or aberrant localization. These results suggest that abnormalities in the AQP3/PLD2 signaling module correlate with hyperproliferation in psoriasis and the NMSCs.",
keywords = "Aquaporin-3, Basal cell carcinoma, Epidermis, Keratinocytes, Phospholipase D2, Skin, Skin cancer, Squamous cell carcinoma",
author = "Voss, {Kristen E.} and Bollag, {Roni Jacob} and Nicole Fussell and Charya By and Sheehan, {Daniel J} and Bollag, {Wendy B}",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00403-011-1136-x",
language = "English (US)",
volume = "303",
pages = "591--600",
journal = "Archives of Dermatological Research",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders

AU - Voss, Kristen E.

AU - Bollag, Roni Jacob

AU - Fussell, Nicole

AU - By, Charya

AU - Sheehan, Daniel J

AU - Bollag, Wendy B

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Non-melanoma skin cancers (NMSCs) and psoriasis represent common hyperproliferative skin disorders, with approximately one million new NMSC diagnoses each year in the United States alone and a psoriasis prevalence of about 2% worldwide. We recently demonstrated that the glycerol channel, aquaporin-3 (AQP3) and the enzyme phospholipase D2 (PLD2) interact functionally in epidermal keratinocytes of the skin to inhibit their proliferation. However, others have suggested that AQP3 is pro-proliferative in keratinocytes and is upregulated in the NMSC, squamous cell carcinoma (SCC). To evaluate the AQP3/PLD2 signaling module in skin diseases, we determined their levels in SCC, basal cell carcinoma (BCC) and psoriasis as compared to normal epidermis. Skin biopsies with the appropriate diagnoses (10 normal, 5 SCC, 13 BCC and 10 plaque psoriasis samples) were obtained from the pathology archives and examined by immunohistochemistry using antibodies recognizing AQP3 and PLD2. In normal epidermis AQP3, an integral membrane protein, was localized mainly to the plasma membrane and PLD2 to the cell periphery, particularly in suprabasal layers. In BCC, AQP3 and PLD2 levels were reduced as compared to the normal-appearing overlying epidermis. In SCC, AQP3 staining was "patchy," with areas of reduced AQP3 immunoreactivity exhibiting positivity for Ki67, a marker of proliferation. PLD2 staining was unchanged in SCC. In psoriasis, AQP3 staining was usually observed in the cytoplasm rather than in the membrane. Also, in the majority of psoriatic samples, PLD2 showed weak immunoreactivity or aberrant localization. These results suggest that abnormalities in the AQP3/PLD2 signaling module correlate with hyperproliferation in psoriasis and the NMSCs.

AB - Non-melanoma skin cancers (NMSCs) and psoriasis represent common hyperproliferative skin disorders, with approximately one million new NMSC diagnoses each year in the United States alone and a psoriasis prevalence of about 2% worldwide. We recently demonstrated that the glycerol channel, aquaporin-3 (AQP3) and the enzyme phospholipase D2 (PLD2) interact functionally in epidermal keratinocytes of the skin to inhibit their proliferation. However, others have suggested that AQP3 is pro-proliferative in keratinocytes and is upregulated in the NMSC, squamous cell carcinoma (SCC). To evaluate the AQP3/PLD2 signaling module in skin diseases, we determined their levels in SCC, basal cell carcinoma (BCC) and psoriasis as compared to normal epidermis. Skin biopsies with the appropriate diagnoses (10 normal, 5 SCC, 13 BCC and 10 plaque psoriasis samples) were obtained from the pathology archives and examined by immunohistochemistry using antibodies recognizing AQP3 and PLD2. In normal epidermis AQP3, an integral membrane protein, was localized mainly to the plasma membrane and PLD2 to the cell periphery, particularly in suprabasal layers. In BCC, AQP3 and PLD2 levels were reduced as compared to the normal-appearing overlying epidermis. In SCC, AQP3 staining was "patchy," with areas of reduced AQP3 immunoreactivity exhibiting positivity for Ki67, a marker of proliferation. PLD2 staining was unchanged in SCC. In psoriasis, AQP3 staining was usually observed in the cytoplasm rather than in the membrane. Also, in the majority of psoriatic samples, PLD2 showed weak immunoreactivity or aberrant localization. These results suggest that abnormalities in the AQP3/PLD2 signaling module correlate with hyperproliferation in psoriasis and the NMSCs.

KW - Aquaporin-3

KW - Basal cell carcinoma

KW - Epidermis

KW - Keratinocytes

KW - Phospholipase D2

KW - Skin

KW - Skin cancer

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=80054124218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054124218&partnerID=8YFLogxK

U2 - 10.1007/s00403-011-1136-x

DO - 10.1007/s00403-011-1136-x

M3 - Article

VL - 303

SP - 591

EP - 600

JO - Archives of Dermatological Research

JF - Archives of Dermatological Research

SN - 0340-3696

IS - 8

ER -